An in vivo method for visualizing flow dynamics of cells within corneal lymphatics [0.03%]
一种可视化角膜淋巴管内细胞流体动力学的体内方法
Beatrice Bourghardt Peebo,Per Fagerholm,Neil Lagali
Beatrice Bourghardt Peebo
Background: Monitoring the trafficking of specific cell populations within lymphatics could improve our understanding of processes such as transplant rejection and cancer metastasis. Current methods, however, lack appropr...
An experimental lymphoscintigraphy study in an acute unilateral deep venous thrombosis model [0.03%]
急性单侧深静脉血栓动物模型淋巴显像实验研究
Zehra Pınar Koç,Oktay Burma,Ayhan Uysal et al.
Zehra Pınar Koç et al.
Background: The aim of this study is to investigate the effect of both inguinal exploration and deep venous thrombosis on lymphatic flow in an experimental model of unilateral acute obstruction of the femoral vein. ...
Saadet Ugur,Cumhur Arıcı,Muhittin Yaprak et al.
Saadet Ugur et al.
Introduction: Secondary lymphedema is one of the major important long-term complications of breast cancer treatment. The aim of this study is to determine patient- and treatment-related risk factors of lymphedema in breas...
Factors affecting the preoperative and postoperative extracellular fluid in the arm on the side of breast cancer: a cohort study [0.03%]
乳腺癌患者术前术后患侧上肢细胞外液影响因素的队列研究
Sharon L Kilbreath,Kathryn M Refshauge,Leigh C Ward et al.
Sharon L Kilbreath et al.
Background: To explore what factors affect volume of extracellular fluid (ECF) in the arm on the side of surgery pre- and postoperatively and to determine the value of knowing preoperative ECF volume for diagnosis of lymp...
The multicomponent medication lymphomyosot improves the outcome of experimental lymphedema [0.03%]
复方药物淋巴肌苷口服液可改善实验性淋巴水肿的疗效
Alex P Keim,Justin R Slis,Uziel Mendez et al.
Alex P Keim et al.
Background: Secondary lymphedema is a life-long disease of painful tissue swelling that often follows axillary lymph node dissection to treat breast cancer. It is hypothesized that poor lymphatic regeneration across the o...
Farzaneh Shariati,Hasan Ravari,Gholamhossein Kazemzadeh et al.
Farzaneh Shariati et al.
Primary lymphedema tarda is considered as a congenital disease with late presentation. Primary lymphedema tarda usually affects lower limbs, and primary lymphedema tarda of the upper limbs usually accompanies lower limb lymphedema. In the c...
Lymphatic muscle cells in rat mesenteric lymphatic vessels of various ages [0.03%]
不同年龄段大鼠肠系膜淋巴管平滑肌细胞的研究
Eric A Bridenbaugh,Irina Tsoy Nizamutdinova,Daniel Jupiter et al.
Eric A Bridenbaugh et al.
Background: Recent studies on aging-associated changes in mesenteric lymph flow in situ demonstrated predominance of the severe negative chronotropic effect of aging on the contractility of aged mesenteric lymphatic vesse...
Characterization of cells expressing lymphatic marker LYVE-1 in macaque large intestine during simian immunodeficiency virus infection identifies a large population of nonvascular LYVE-1(+)/DC-SIGN(+) cells [0.03%]
在猴免疫缺陷病毒感染期间，恒河猴大肠淋巴管标志物LYVE-1表达细胞的特征鉴定发现了一大批非血管LYVE-1+/DC-SIGN+细胞
Yang-Kyu Choi,Beth A Fallert Junecko,Cynthia R Klamar et al.
Yang-Kyu Choi et al.
Abstract LYVE-1 is a marker expressed by lymphatic endothelial cells (LECs) that line the lymphatic endothelium. Through studies designed to examine potential changes in expression of LYVE-1 in cynomolgus macaque colon tissues during the co...
Is lymphatic endoglin expression a risk marker for breast cancer metastasis? Results of a pilot study [0.03%]
淋巴内皮因子表达是乳腺癌转移的风险标记吗？初步研究结果报告
S Clasper,S O Ogunbiyi,G Baxter et al.
S Clasper et al.
Background: Studies have identified endoglin as a biological marker that is overexpressed on the microvessels of certain solid cancers (breast, colorectal cancer, and head and neck squamous cell cancers). There is, at pre...
Systematic review of quality of life and patient reported outcomes in patients with oncologic related lower extremity lymphedema [0.03%]
肿瘤相关下肢淋巴水肿患者的生活质量和患者报告结果的系统评价
Yeliz Cemal,Sarah Jewell,Claudia R Albornoz et al.
Yeliz Cemal et al.
Background: Lower limb lymphedema (LLL) is a common complication of cancer treatment. The disease is chronic and progressive with no cure. Although a common and significant source of morbidity, the impact of this conditio...